Indian J Pharm Close
 

Table 3: Phase III Trials Showing Superiority of EGFR-TKIs Over First-line Chemotherapy in EGFR-mutated NSCLC Patients[28]

Table 3: Phase III Trials Showing Superiority of EGFR-TKIs Over First-line Chemotherapy in EGFR-mutated NSCLC Patients<sup>[28]</sup>